BGC20-0582
Phase 2Small molecule
BGC20-0582 is one of 6 small molecule programs targeting Lice Infestation. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Lice Infestation
#DrugCompanyPhaseTrials
1Avelox
BayerApproved
Stromectol
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Natroba
DDeciphera Pharmaceuticals, LLC
Approved
Xeglyze
LLnhc
Phase 3
Ha44
DDr. Reddy's Laboratories Limited
Phase 2
BGC20-0582
BBoston Scientific Corporation
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BGC20-0582. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- BBoston Scientific Corporation